( 您好!臺灣時間:2021/05/19 09:35
字體大小: 字級放大   字級縮小   預設字形  


研究生(外文):Sung-Wen Chang
論文名稱(外文):mRNA expression of TNF-α、TGF-β、IFN-γcytokines in cultured peripheral blood mononuclear cells in patients with oral submucous fibrosis and leukoplakia
指導教授(外文):Tien-Yu ShiehKee-Lung Chang
外文關鍵詞:oral submucous fibrosisleukoplakiacytokineTNF-αTGF-βIFN-γ
  • 被引用被引用:0
  • 點閱點閱:132
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:1
腔白斑症被認為是口腔癌的癌前期病變,因此研究這些口腔黏膜疾病的致病因對於口腔癌的預防和治療有其重要性。口腔癌前期黏膜病變與免疫系統有關係,而細胞激素(Cytokine)在調控人體免疫反應上扮演很重要的角色,所以人體周邊血液單核細胞產生細胞激素能力之測定日益受到重視,並已成為評估病人細胞性免疫能力的重要基準。本研究先培養口腔黏膜下纖維化、口腔白斑症患者的周邊血液單核細胞,然後以RT-PCR之方法來偵測口腔黏膜下纖維化、口腔白斑症患者的周邊血液單核細胞內控制分泌TNF-α、TGF-β及IFN-γ這些細胞激素的單核細胞之細胞核內的mRNA表現量與具正常口腔黏膜者之差異性。結果發現口腔黏膜下纖維化之TNF-α及IFN-γ mRNA表現量均較具正常口腔黏膜者微高,而TGF-β則可能因口腔黏膜下纖維化疾病分期不同而有不同表現,但均不具有統計學上之差異。而口腔白斑症患者之TNF-α及IFN-γ mRNA表現量亦較具正常口腔黏膜者微高,但是TGF-β mRNA表現量卻比具正常口腔黏膜者低,但均不具有統計學上之差異。

Oral cancer has become a series health issue in Taiwan, and it is believed that oral submucous fibrosis(OSF) and leukoplakia are precancerous lesions. Therefore to focus on the etiology of these oral mucosal lesions is very important for the prevention and treatment of oral cancer. Oral precancerous mucosal lesions have a close link to the immune systems and cytokines have played an important role on how to regulate the immune systems. It is important that human peripheral blood mononuclear cells could produce cytokines and it has become a guideline of how to evaluate the cellular immunity of these patients. In our study, we cultured the peripheral mononuclear cells of the patients with OSF and leukoplakia and detected the mRNA expression of TNF-α、TGF-β and IFN-γ by RT-PCR method. Our result showed that the TNF-α and IFN-γ mRNA expression is higher in OSF patients and TGF-β may have different expressions because of different stages of OSF. TNF-α and IFN-γ mRNA expression is higher in leukoplakia patients but TGF-β mRNA expression is lower in patients with leukoplakia than in normal patients.

壹、 摘要 ------------------1
貳、 緒論 ------------------3
參、 文獻回顧 --------------7
肆、 研究方法 -------------14
伍、 結果 -----------------22
陸、 討論 -----------------30
柒、 參考文獻 -------------36
捌、 圖表 -----------------46

1.Lu CT, Yen YY, Ho CS, et al. A case-control study of oral cancer in Changhua County, Taiwan. J Oral Pathol Med 1996; 25:245-248.
2.Anonymous. Health and vital statistics: 1991-1995. Taiwan: Department of Health, Executive Yuan. ROC.
3.Bouquot JE, Weiland LH Kurland LT, et al: Leukoplakia and carcinoma in situ synchronously associated with invasive oral/oropharyngeal carcinoma in Rochester, Minn., 1935-1984. Oral Surg Oral Med Oral Pathol 1988; 65:199-207.
4.Gupta PC, Mehta FS, Daftary DK, et al: Incidence rates of oral cancer and natural history of oral precancerous lesions in a larger follow-up study of Indian Villages. Community Dent Oral Epidemiol 1980; 8:287-333.
5.Silverman S, Gorsky M, Lozada F: Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer 1984; 53: 563-568.
6.Vanwyk CW, Grobler RAF, Martell RW, Hammond MG: HLA-antigens in oral submucous fibrosis. J Oral Patho Med 1994; 23:23-27.
7.Rajendran R, Sugathan CK, Remani P, Ankathil R, Vijayakumar T. Cell mediated and humoral immune responses in oral submucous fibrosis. Cancer 1986 Dec 15; 58: 2628-2631.
8.Gallo O, Pinto S, Boccuzzi S, et al: Monocyte tumor necrosis factor production in head and neck squamous cell carcinoma. Laryngoscope 1992;102:447-450.
9.Parks RR, Yan SD, Huang CC. Tumor necrosis factor-alpha production in human head and neck squamous cell carcinoma. Laryngoscope 1994 Jul; 104:860-864.
10.Kannan R, Bijur GN, Mallery SR, Beck FM, Sabourin CL, Jewell SD, Schuller DE, Stoner GD. Transforming growth factor-alpha overexpression in proliferative verrucous leukoplakia and oral squamous cell carcinoma: an immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82:69-74.
11.Haque MF, Meghji S, Khitab U, Harris M et al: Oral submucous fibrosis patients have altered levels of cytokine production. J Oral Patho Med 2000; 29:123-128.
12.許瀚仁 高雄醫學大學牙醫學研究所1997年碩士論文: 檳榔塊對於黏膜下纖維化及鱗狀上皮細胞癌患者在周邊血液單核球培養中細胞激素生成影響之研究; 謝天渝, 張基隆指導
13.Wahl SM: The role of lymphokines and monokines in fibrosis. Ann N Y Acad Sci 1985;460: 224-231.
14.Freundlich B, Bomalaski, J S, Neilson E, Jimenez SA: Regulation of fibroblast proliferation and collagen synthesis by cytokines. Immunol Today 1986;7: 303-307.
15.Leibovitch SJ, Ross R: A macrophage-dependent factor that stimulates the proliferation of fibroblasts in vitro. Am J Pathol 1976;84: 501-514.
16.Kahaleh MB, Sherer GK, Leroy EC: Endothelial injury in scleroderma. J Exp Med 1979;149:1326-1335.
17.Fleischmajer R, Perlish JS, West WP: Ultrastructure of cutaneous cellular infiltrates in scleroderma. Arch Dermatol 1977; 113: 1661 —1666.
18.Ursula EB, Sabine von K, Wifried S, Carola SF, Jurgen SM:Cytokine levels in whole blood cell cultures as parameters of the cellular immunologic activity in patients with malignant melanoma and basal cell carcinoma. Cancer 1993;71:231-236.
19.Schwartz J: atrophia idiopathia (tropica)mucosae oris. Demonstrated at the eleventh international dental congress, London, 1952.
20.Su JP: Idiopathic scleroderma of the mouth. Report of three cases. Arch otolaryngol 1954; 59:330-332.
21.Lal D: Diffuse oral submucous fibrosis. J All-Indian Dent Assoc 1953; 26:1-3.
22.Rao ABN: Idiopathic palatal fibrosis. Br J Surg 1962; 50:23-25.
23.Joshi SG: Submucous fibrosis of palate and pillar. Indian J Otolaryngol 1953; 4:1-4.
24.Pindborg JJ, Sirsat SM: Oral submucous fibrosis. Oral Med Oral Surg Oral Pathol 1966; 764-779.
25.Jian XC, Liu SF, Shen ZH, Yang YH. Histomorphology of oral submucous fibrosis. Report of 24 cases. Chung Hua I Hsueh Tsa Chih 1988; 101:505-509.
26.Paymaster JC. Cancer of the buccal mucosa; a clinical study of 650 cases in Indian patients. Cancer 1956; 9:431-435.
27.Pindborg JJ. Is submucous fibrosis a precancerous condition in the oral cavity? Int Dent J 1972; 22:474-480.
28.Gupta PC, Mehta FS, Daftary DK, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villages. Community Dent Oral Epidemiol 1980; 8:287-333.
29.Murti PR, Bhonsle RB, Pindborg JJ, et al. Malignant transformation rate in oral submucous fibrosis over 17 years period. Community Dent Oral Epidemiol 1985; 13:340-341.
30.黃志浩, 謝天渝: 轉型生長因子-β在口腔黏膜下纖維性病變之免疫組織化學表現. J Academy Formosan Stomatolog 1999;15:227- 239.
31.Sato M, Yohsida Y, Yanagawa T, Yura Y, Urata M, Nitta T, Azuma M and Hayashi Y.: Therapeutic effect of human fibroblast interferon on premalignant lesions arising in oral mucosa. A pilot study. Int J Oral Surg. 1985; 14:184-194.
32.Urata M, Yoshida H, Yanagawa T, Yura Y, Furumoto N, Azuma M, Hayashi Y and Sato M. : Interferon activity and its characterization in the sera of patients with premalignant lesions arising in oral mucosa. Int J Oral Maxillofac Surg 1996 Apr;15:134-147.
33.Carswell EA, Old LJ, Kassel RL, et al: An Endotoxin serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72: 3666- 3670.
34.Fiers W, Beyaert R, Bronchkaert P, et al.: TNF: Its potential as an anti-tumor agent. Dev Biol Stand 1987;69:143-151.
35.Nylor MS, Malik STA, Stamp GWH, et al: in situ detection of tumor necrosis factor in human ovarian cancer specimens. Int J Cancer 1990; 26:1027-1030.
36.Takeyama H, Wakamiya N, O Hara C, et al.: Tumor necrosis factor expression by human ovarian carcinoma in vivo. Cancer Res 1991;51: 4476-4480.
37.Lugassy C and Escande JP.: Immunolocation of TNF-α / cachectin in human melonoma cells: Studies on co-cultivated malignant Melanoma. J invest Dermatol 1991; 96:238-242.
38.Mannel DN, Ruschoff J, Orosz P. The role of TNF in tumor growth and metastasis. Res Immunol. 1993;144:364-369.
39.Aderka D, Engelmann H, Maor Y, et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992;175:323-329.
40.Roberts AB, Anzano MA, Lamb LC, Smith JM and Sporn MB. Antagonistic actions of retinoic acid and dexamethasone on anchorage-independent growth and epidermal growth factor binding of normal rat kidney cells. Proc Natn Acad Sci USA 1981;78: 5339-5343.
41.Assoian RK, Komoroya A, Meyers CA, Miller DM and Sporn MB. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J boil chem. 1983; 258: 7155-7160.
42.Sporn MB, Ward JM, Sodek J. Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. Science 1983;219: 1329-1331.
43.Tucker RF, Volkenant ME, Baghum EL and Moses HL. Comparison of intra-and extracellular transforming growth factors from nontransformed and chemically transformed mouse embryo cells. Cancer Res 1983;43: 1581-1586.
44.Ronald A, Ignotz, Joan Massaque: Transforming growth factor beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix: J Biol Chem 1986; 261:4337-4345.
45.Roberts AB, Sporn MB, Assoian PK, Smith JM, Roche NS, Wake field LM, Heine V, Liotta LA, Falanga V, Kehrl JM and Fauci A. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83: 4167-4171.
46.Tucker RF, Shipley GD, Moses HL and Holley RW. Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science 1984;226: 705-707.
47.Iwata K, Fryling CM, Knott WB and Todaro G. Isolation of tumor cell growth-inhibiting factors from a human rhabdomyosarcoma cell line. J Cancer Res. 1985;45: 2689-2694.
48.Pierson BA, Gupta K, Hu WS, Miller JS: Human natural killer cell expression in regulated by thrombospondin mediated activation of transforming growth factor beta 1 and independent accessory cell derived contact and soluble factors: Blood 1996; 87:180-189
49.Sporn MB, Roberts AB: Transforming growth factor beta: recent progress and new challenges: J cell Biol 1992; 119:1017-1021
50.Heine UI, Munoz EF, Flanders KC, Ellingsworth RC, Lam HYP, Thompson NL, Roberts AB, Sporn MB: Role of transforming growth factors beta in the development of the mouse embryo: J Cell Biol 1987; 105: 2861-2876.
51.Krummel TM, Michna BA, Thomas BL, Spon MB, Nelson JM, Salzberg AM, Cohen IK, Diegelmann RF: Transforming growth factors beta induces fibrosis in a fetal wound model. J Pediatr Surg 1988; 23:647-652.
52.Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Deuel TF: Accelerated healing of incisional wounds in rates induced by transforming growth factors beta: Science 1987; 237:1333-1336.
53.Gao Yijun, Ling Tianyou, Wu Hanjiang, et al. Expression of transforming growh factorβ1 in keratinocytes of oral submucous fibrosis tissue. Chin J Stomatol, July 1997; 32: 239-241.
54.Desmyter J, Ray MB, Degrotte J, Bradburne AF, Desmet, VJ, Edy VG, Billiau A, and De somer P: Administration of human fibroblast interferon in chronic hepatitis-B infection. Lancet 1976; 2:645-647.
55.Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, and Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patient with chronic active hepatitis. N Engl. J Med 1976;295:517-522
56.Pazin GJ, Armstrong JA and Lam MT.: Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. N Engl. J Med 1979;301:225-230.
57.Blomagren H, Cantell K, Langergren C, Ringborg V and Strander H: Interferon therapy in Hodgkin’s disease. Acta Med Scand. 1976:199:527-532.
58.Gutterman JU, Blumenschein GR, Alexmanian R, Hwee-Yong YAP, Buzder AV, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M and Pestka S: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann. Intern Med. 1980; 93:399-406.
59.De Maeyer EJ, De Maeyer-guignard and Vandeputte M.: Inhibition by interferon of delayed-type hypersensitivity in the mouse. Proc Nat Acad Sci, USA 1975;72:1753-1757.
60.Gressor I: On the varied biologic effects of interferon. Cell Immunol. 1977;34:406-415.
61.Hooks JJ, Moutsopoulos HM, geis SA, Stahl NI, Decker JL and Notkins Al: Immune interferon in the children of patients with autoimmune disease. N Engl J Med. 1979;301:5-8.
62.Mahmoud F, Abul H, Al-Seleh Q, Morgan G, Haines D, Al-Ramly M, Burleson J and Kreutzer D: Differential expression of interferon gamma by mitogen-stimulated peripheral blood mononuclear cell among Kuwaiti Psoriasis patients. J Dermatol 1999; 26:23-28.
63.Granstein RD, Rook A, Flotte TJ, et al. A controlled trial of intra-lesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings. Arch Dermatol 1990; 126:1295-1302.
64.Kahan A, Amor B, Menkej CJ, Stranch G. Recombinant interferon gamma in the treatment of systemic sclerosis. Am J Med 1989; 87:272-277.
65.Hein R, Behr J, Hundgen M, et al. Treatment of systemic sclerosis with gamma interferon. Br J Dermatol 1992; 126:496-501.
66.Haque MF, Meghji S, Nazir R, Harris M. Interferon gamma ( IFN-γ) may reverse oral submucous fibrosis. J Oral Pathol Med 2001; 30: 12-21.
67.Canniff JP, Harvey N: The aetiology of oral submucous fibrosis: the stimulation of collagen synthesis by extracts of areca nut. Int J Oral Surg 1981; 10:Suppl 1:163-167.
68.Harvey W, Scatt A, Meghji S, Caniff JP: Stimulation of human buccal mucosa fibroblasts in vitro by betel-nut alkaloids. Archs oral Biol 1986; 31:45-49.
69.Pindborg JJ, Sirsat SM. Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol 1966; 22:764-799.
70.Mizel SB. The interleukins. FASEB J 1989; 3: 2379-2388.
71.Yang YH, Lee HY, Tung S, et al: Epidermiological survey of oral submucous fibrosis and leukoplakia in aborigines of Taiwan. J Oral Pathol Med 2001 Apr ;30:213-219.
72.Strnulis-Praeger BM, Gilchrest BA: In-vitro studies of aging. Clin Geriatr Med 1989; 5:23-40.
73.Sauder DN, Stanulis-Praeger BM, Gilchrest BA: Autocrine growth stimulation of human keratinocytes by epidermal cell-derived thymocyte activating factor: Implications for skin aging. Arch Dermatol Res 1988; 280:71-76.
74.Stanulis-Praeger BM, Gilchrest BA: Growth factor responsiveness declines during adulthood for human skin-derived cells. Mech Aging Devel 1986; 35:185-189
75.Compton C, Tong Y, Trookman N, Zhao H and Roy D. TGF-β1 gene expression in cultured human keratinocytes does not decrease with biologic age. J Invest Dermatol 1994; 103:127-133.
76.Yeudall WA, Campo MS. Human papillomavirus DNA in biopsies of oral tissues. J Gen Virol 1991;72:173-176.
77.Anderson JA, Irish JC, Maclachlin CM, Ngan BY. H-ras oncogene mutation and human papillomavirus infection in oral carcinomas. Arch Otolaryngol Head Neck Surg 1994;120:755-760.
78.吳崇維 高雄醫學大學牙醫學研究所2000年碩士論文: 以聚合酶連鎖反應偵測口腔鱗狀上皮細胞癌組織之人類疣狀病毒與EB病毒之研究; 謝天渝, 張基隆指導

第一頁 上一頁 下一頁 最後一頁 top
1. 口腔鱗狀上皮細胞癌患者在周邊血液單核細胞之細胞激素mRNA表現之研究
2. MatrixMetalloproteinases-2和HER-2基因多型性與台灣口腔鱗狀上皮細胞癌患者之相關性分析
3. p53與COX-2基因多型性與口腔鱗狀上皮細胞癌及口腔癌前病變的相關性分析
4. 女性純粹毒品濫用者、合併使用毒品與檳榔者周邊血液單核細胞分泌細胞激素能力之研究
5. 腫瘤壞死因子之基因標記多型性與口腔鱗狀細胞癌之相關性研究
6. 嚼食檳榔之口腔鱗狀細胞癌患者在不同療程之周邊血液單核細胞腫瘤壞死因子及其受體釋出探討
7. 以聚合連鎖反應偵測口腔鱗狀上皮細胞癌組織之人類疣瘤病毒及EB病毒之研究
8. 檳榔塊對於黏膜下纖維化及鱗狀上皮細胞癌患者在周邊血液單核球培養中細胞激素生成影響之研究
9. Thrombin 誘導頰黏膜纖維母細胞 CTGF 表現機轉及以EGCG 治療口腔黏膜下纖維化症潛力之研究
10. Arecoline誘導肝癌細胞HA22T/VGH走向失巢凋亡(anoikis)著重STAT3及RhoA活化之機制探討
11. 檳榔素對於人類臍靜脈內皮細胞氧化傷害之探討
12. TGF-β 誘導頰黏膜纖維母細胞 CTGF 表現機轉及以Curcumin 治療口腔黏膜下纖維化症之研究
13. 探討硫化軟骨素、維生素C及維生素D對骨關節炎之防護機制
14. 探討精胺酸合併維生素C在人類肝癌細胞株HA22T/VGH中抑制五碳醣磷酸代謝途徑並誘發氧化壓力之研究
15. 探討維生素C、礦物元素硒及硫化軟骨素對緩解骨關節炎之效用與機制